About Us

WHO WE ARE

Created in May 2018, Zionexa is an international company developing and commercializing Molecular Imaging Companion Diagnostics (CDx) for targeted therapies in Oncology aimed to improve patients’ pathway and quality of life.

Zionexa is a spin-off of Cyclopharma, a radiopharmaceutical company producing and commercializing biomarkers in France.

OUR MISSION

We develop Molecular Imaging CDx ​for targeted therapies that will transform oncology ​by improving the patient’s pathway and quality of life. ​Within a PET Scan (Positron Emission Tomography) exam, biomarkers help Oncologists and Nuclear Medicine Physicians to personalize the treatment, based on the localization and characteristics of the tumors.

MEET OUR TEAM

Meet our team of experts in CDx Imaging for Oncology:

Bernard Landes

Chairman & CEO

  • Former General Manager of Cyclopharma
  • 25 years of experience in pharmaceutical industry and IT

Peter Webner

CEO, US

  • Former General Manager of Zevacor Pharma
  • 25 years of experience in radiopharmaceutical industry

Jean-Bernard Deloye

Head of Market Access

  • Former Deputy General Manager of Cyclopharma
  • 25 years of experience in radiopharmaceutical industry

Yann Bouvet

Head of R&D

  • Former Pharmaceutical and Inustrial Development Director of Cyclopharma
  • 10 years of experience in R&D projects

Jerome Francillard

CFO

  • Former CFO of Energy Pool
  • 15 years of experience in consulting and financing growth

Together, we are dedicated to

transforming Oncology >

VIEW OUR PIPELINE